← Human Trials & Peer-Reviewed Studies
Teriparatide Followed by Denosumab in Premenopausal Idiopathic Osteoporosis: Bone Microstructure and Strength by HR-pQCT
Plain-language guide to PMID 36335582 (2023): placebo-controlled randomized controlled trial study of Teriparatide in 41 women, osteoporosis and bone density.
Key Facts
- PMID
- 36335582
- Journal
- Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Agarwal S et al. (11 authors)
- DOI
- 10.1002/jbmr.4739
What This Study Did, in Plain Language
What Was Tested
Researchers studied Teriparatide in the context of osteoporosis and bone density in this randomized controlled trial publication.
Premenopausal women with idiopathic osteoporosis (PreMenIOP) have marked deficits in skeletal microstructure.
The researchers conducted preplanned analyses of high-resolution peripheral quantitative computed tomography (HR-pQCT) scans from teriparatide and denosumab extension studies to measure effects on volumetric BMD (vBMD), microarchitecture, and estimated strength at the distal radius and tibia.
Who Took Part
The study group was 41 women.
PubMed tags the participants as women only.
How the Study Was Run
The design is described as randomized and placebo-controlled.
Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Some women received a placebo instead of Teriparatide, giving a reference point.
A time span of 6 months appears in the methods.
What Was Measured
The researchers conducted preplanned analyses of high-resolution peripheral quantitative computed tomography (HR-pQCT) scans from teriparatide and denosumab extension studies to measure effects on volumetric BMD (vBMD), microarchitecture, and estimated strength at the distal radius and tibia.
Primary outcomes were percentage change in vBMD, microstructure, and stiffness after teriparatide and after denosumab.
The subject headings attached to it are Absorptiometry, Photon, Bone and Bones, Bone Density, Denosumab, Osteoporosis, Radius and Teriparatide.
Author keywords: BONE MICROSTRUCTURE, BONE STRENGTH and PREMENOPAUSAL OSTEOPOROSIS.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Teriparatide in 41 women in people with osteoporosis and bone density over 6 months.
The publication is from 2023 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.
More context: the Teriparatide compound page, Osteoporosis and bone density research.
Our Notes on the Compound
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.